Drug Interaction Between Gleevec (Imatinib) and Eliquis (Apixaban)
Imatinib is a moderate CYP3A4 inhibitor and P-glycoprotein (P-gp) inhibitor that can increase apixaban exposure, but no dose adjustment of apixaban is required when co-administered with imatinib at standard doses (400-600 mg daily).
Mechanism of Interaction
Imatinib inhibits CYP3A4, the primary metabolic pathway for apixaban, and also inhibits P-gp and BCRP transporters involved in apixaban elimination 1. This creates a pharmacokinetic interaction that theoretically increases apixaban plasma concentrations. However, the magnitude of this interaction with imatinib specifically has not been extensively studied in controlled trials.
Clinical Evidence and Magnitude
The available evidence suggests the interaction is clinically manageable:
Comparative data from similar inhibitors: Studies with cyclosporine (a combined CYP3A4/P-gp/BCRP inhibitor) showed apixaban AUC increased by only 20% and Cmax by 43%, which remained within the safety margins established during apixaban's clinical development program 2. Imatinib is a less potent inhibitor than cyclosporine.
Imatinib's inhibitory profile: Imatinib is metabolized by CYP3A4/3A5 and can competitively inhibit these enzymes 1, but it is considered a moderate rather than strong inhibitor, suggesting a more modest effect on apixaban levels compared to potent inhibitors.
Real-world safety data: A systematic review of apixaban drug interactions found that pharmacokinetic interactions are often poorly detected in clinical practice, with most adverse events related to pharmacodynamic interactions (additive bleeding risk) rather than pharmacokinetic changes 3.
Practical Management Recommendations
Continue standard apixaban dosing (5 mg twice daily, or 2.5 mg twice daily if dose-reduction criteria are met) when co-administered with imatinib 400-600 mg daily. The dose-reduction criteria for apixaban remain: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (at least 2 of 3 criteria).
Monitoring Strategy
- Baseline assessment: Check CBC with platelets, renal function (creatinine clearance), and hepatic function before initiating combination therapy 4
- Enhanced bleeding surveillance: Monitor hemoglobin, hematocrit, and platelets every 2 weeks for the first month, then monthly or as clinically indicated 4
- Watch for bleeding signs: Educate patients about bleeding symptoms (unusual bruising, prolonged bleeding from cuts, blood in urine/stool, severe headache)
- Renal function monitoring: Reassess creatinine clearance every 3-6 months, as both drugs require renal dose adjustments
Critical Caveats
Avoid this combination in patients with:
- Moderate to severe renal impairment (CrCl 15-29 mL/min) - both drugs require dose reduction and the combined effect increases bleeding risk
- Severe hepatic impairment - imatinib requires 25% dose reduction 5, and apixaban exposure increases unpredictably
- Active gastric or gastroesophageal malignancies - DOACs carry higher bleeding risk in these patients 4
Drug-drug-disease interaction: If the patient is taking imatinib for gastrointestinal stromal tumor (GIST), particularly with gastric or gastroesophageal involvement, strongly consider LMWH instead of apixaban as the preferred anticoagulant 4. The NCCN guidelines specifically note that apixaban may be safer than other DOACs for gastric lesions but still carries increased hemorrhage risk 4.
When to Consider Alternatives
Switch to LMWH (enoxaparin 1 mg/kg SC every 12 hours or dalteparin 200 units/kg SC daily) if:
- Patient develops any bleeding complications
- Creatinine clearance falls below 30 mL/min
- Imatinib dose escalation to 800 mg daily is required (increases CYP3A4 inhibition)
- Gastrointestinal malignancy is present
Additional Pharmacodynamic Considerations
Beyond the pharmacokinetic interaction, monitor for additive myelosuppression. Imatinib commonly causes thrombocytopenia 5, which compounds bleeding risk when combined with anticoagulation. If platelets fall below 50 × 10⁹/L, hold both medications until platelets recover to ≥75 × 10⁹/L, then resume at reduced doses per imatinib prescribing guidelines 5.
The bottom line: Standard apixaban dosing is appropriate with imatinib 400-600 mg daily, but requires enhanced bleeding surveillance and careful patient selection, avoiding those with GI malignancies or significant renal/hepatic impairment.